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Abstract The human folate receptor (FR) is overexpressed in
ovarian carcinoma. FR transcripts are heterogeneous due to the
use of two promoters, P1 and P4, and alternative splicing of exon
3. RNase protection assay and RT-PCR revealed higher levels of
the transcripts that include exon 3 in lines and specimens from
ovarian carcinoma. A P1^chloramphenicol acetyltransferase
(CAT) construct containing exon 3 demonstrated efficient
reporter expression only in ovarian carcinoma. 5P and 3P deleted
variants of the P1^CAT construct were analyzed by RT-PCR of
the exogenous transcripts and reporter activity. A 5P splice site
and 35 bp downstream intronic region of exon 3 appeared to
regulate enhanced FR expression in ovarian carcinoma. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The human K folate receptor (KFR), a 38 kDa membrane
glycoprotein, is selectively overexpressed in 90% of non-muci-
nous ovarian carcinomas and in some other malignant tissues.
The receptor has also been detected in the epithelium of the
proximal tubules of kidney and a few other normal cell types
[1], but not in normal ovarian surface epithelium. In ovarian
carcinoma cell lines [2] and normal human tissues [3], the
abundance of KFR transcripts is proportionate to receptor
expression, suggesting that transcriptional regulation modu-
lates at least in part expression of the receptor. The gene is
composed of seven exons spanning approximately 6.7 kb. The
open reading frame (ORF) is encoded by exons 4 through 7,
while the reported 5P non-coding sequence (NCS) of the
cDNA isoforms are encoded by exons 1 through 4 [4]. The
KFR transcripts cloned from cDNA expression libraries from
di¡erent cell lines share common ORF and 3P NCS but show
unique 5P termini [5,6]. This heterogeneity relies on the use of
at least two promoter regions, P1, upstream and internal of
exon 1 and P4, upstream of exon 4 [4]. An additional mech-
anism of transcript diversity, i.e. the inclusion of 66 bp of
alternatively spliced exon 3, was evidenced in the cDNA se-
quences of two di¡erent P1-derived KFR transcripts (clones
#31 and #4/6) isolated from an IGROV1 ovarian carcinoma
cDNA expression library [7].
Here we point out that the inclusion of alternatively spliced
exon 3 of the KFR gene is enhanced in ovarian carcinoma. We
suggest that in the 5P splice site and downstream 35 bp intron
region of exon 3 lies a control element that promotes its
e⁄cient inclusion and is one of the mechanisms that contrib-
utes to the FR expression speci¢city in ovarian carcinoma.
2. Materials and methods
2.1. Materials
The following human tumor cell lines were used: the serous ovarian
carcinomas IGROV1 (J. Benard, Institute G. Roussy, Villejuif,
France), OVCAR3, SKOV3 (both from ATCC), OAW42 (DKFZ
Germany), OVCA432 (R. Knapp, Dana Farber Institute, Boston,
MA, USA), INTOv1 and INTOv2 [8] and the nasopharyngeal carci-
noma KB (ATCC). Total RNA from surgical samples was obtained
from ¢ve patients at di¡erent stages of disease [9]. RNA from normal
human tissues were purchased from Clontech (Palo Alto, CA, USA).
2.2. Plasmids
The constructs with (KBPE1-3-chloramphenicol acetyltransferase
(CAT)) or without (P1PD-CAT) exon 3 were described previously
[4]. The #4/6 ECO construct was obtained by PCR ampli¢cation of
the KBPE1-3 plasmid with the forward primer named #22 (5P-
GAGCTCAAGCTTGGCAAGGGGAGTGTAGAGCAG-3P), that
anneals in exon 1, and a reverse primer that anneals in the 5P CAT
sequence (5P-CTCCTACCCGGGGCAACTGACTGACTGAAATG-
CCTC-3P) ; digestion of the PCR product with HindIII (contained
in forward primer) and EcoRI and cloning in the pCAT basic vector.
#4/6 ECO construct was digested with BamHI, blunt-ended and re-
ligated to generate #4/6 BAM construct. #4/6 XBA construct was
obtained by PCR ampli¢cation of the KBPE1-3 plasmid with the
forward primer #22 and reverse primer that anneal in the 3P of
exon 3 region (5P-AAGCCTTCTAGAGGGCCACGCCGGAGA-
AA-3P).
2.3. RNase protection assay
RNA from cell lines was extracted using the RNeasy total RNA kit
(Qiagen, Hilden, Germany). Total RNA from the normal tissues in-
dicated (25 Wg) or the KB and IGROV1 carcinoma cell lines (10 Wg)
was probed with the IG-1 and L-actin antisense riboprobes. The assay
was performed essentially as described [10]. Comparison of the inten-
sity of the high molecular weight bands with that of the splicing site
(SS) protected fragment was performed with IMAGEQUANT soft-
ware (Molecular Dynamics, Sunnyvale, CA, USA).
2.4. RT-PCR assay
RT-PCR was performed on 1 Wg of total RNA reverse transcribed
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using 50 U of reverse transcriptase and a poly(dT) primer. The result-
ing cDNA (2 Wl) was ampli¢ed using 2 U of Ampli Taq polymerase
and 30-cycle PCR (95‡ 1 min, 58‡C 1 min, 72‡ 1 min). The forward
primer was #22 (see above) and the reverse primer was 5P-CCA-
CCTTCTAGAGCCTGGCTTTTCCTTGTGGTG-3P, that anneals in
exon 4. Total RNA extracted from KB and IGROV1 transfected cells
was ampli¢ed with the following forward and reverse primers:
5P-CTCCTCTCCCAGGAACTGAA-3P, that anneals in the exon
1-exon 3 junction region; and 5P-TCCAGCTGAGCGGTCTG-
GTT-3P speci¢c for CAT-ORF. Quanti¢cation of ethidium bromine
stained PCR products was performed with Eagleye software (Strata-
gene, La Jolla, CA, USA)
2.5. Cells transfection and CAT assay
Cells (1.2U105) were seeded in a 12 well plate and transfected the
following day using the lipofectin method essentially as suggested by
the manufacturer (Gibco BRL). CAT constructs (2.5 Wg) were co-
transfected with pCMV-Luc (0.05 Wg) containing the luciferase gene
downstream from a cytomegalovirus promoter (kindly provided from
Dr. Maria Zajac-Kaye, Bethesda, MD, USA) to control for trans-
fection e⁄ciency. Luciferase and CAT activity were evaluated as de-
scribed [11].
3. Results
3.1. Analysis of the KFR P1 mRNA expression
To establish the relative abundance of KFR P1-derived
transcripts that include alternatively spliced exon 3, an RNase
protection assay performed on a wide panel of normal tissues
was compared to that obtained with two KFR overexpressing
cell lines, IGROV1 ovarian carcinoma and KB nasopharyn-
geal carcinoma. Total RNAs were probed using an antisense
riboprobe (IG1) that contains the 5P NCS of cDNA clone
#4/6 (130 bp) and initial 144 bp of the ORF up to the AvaI
site and 10 bp between the common SS and the beginning of
the ORF (154 bp) (Fig. 1A).
Major bands between 250 and 300 bp, representative of the
Fig. 1. RNase protection analysis of P1 promoter-driven KFR transcripts. A: Schematic representation of the FR gene showing the promoters,
the intron/exon organization and the alternative splicing identi¢ed from the cDNA expression library. Exons are numbered and represented by
boxes. A line represents introns and an arrowhead marks the common splice site upstream of ATG. The lower diagram represents the EcoRI/
AvaI restriction fragment of the KFR cDNA clone #4/6 named IG1. B: Total RNA from the normal tissues or the KB and IGROV1 carcino-
ma cell lines was probed with the IG-1 and L-actin antisense riboprobes.
Fig. 2. Splicing pattern of P1 promoter-driven KFR transcripts by
RT-PCR. A: Total RNA extracted from ovarian carcinoma cell
lines and KFR-non-expressing carcinoma cell line KB. B: Ovarian
tumor surgical specimens. The nine samples analyzed were derived
from one borderline, three primary, and ¢ve metastatic tumors.
Upper (305 bp) and lower (239 bp) bands represent the mRNA iso-
forms containing or excluding exon 3, respectively. The ratio be-
tween the upper and the lower bands was calculated as described in
Section 2.
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IG1 full length protected fragments, were evident in IGROV1
and KB cell lines, detectable in kidney and barely detectable
in lung and placenta. Comparison of the intensity of the high
molecular weight bands with that of the SS protected frag-
ment indicated only weak protection of the KB RNA with the
IG1 riboprobe (10% in KB vs. 47% in IGROV1) (Fig. 1B).
To compare the relative proportions of P1-derived KFR
mRNA isoforms, an RT-PCR-based method was used. Anal-
ysis was performed on equal amounts of total RNA extracted
from: a panel of ovarian carcinoma cell lines and surgical
specimens and as control on IGROV1 and KB cells. The
primers were designed to competitively amplify the mRNAs
containing or lacking exon 3. All ovarian carcinoma cell lines
and surgical specimens, irrespective to the stage of the disease,
revealed a P1-derived mRNA that predominantly includes
exon 3, ranging from 53 to 99% inclusion (Fig. 2), while
KB cells only exhibited 18% exon 3 inclusion.
3.2. Analysis of expression speci¢city
To investigate on the inclusion of exon 3 in ovarian carci-
noma, we transiently transfected IGROV1 and KB cells rep-
resenting exon 3 inclusion and exclusion, respectively. Two
CAT constructs were used: (i) P1PD, which contains the min-
imal P1 promoter region and exon 1; (ii) KBPE1-3, which
contains the same P1PD sequence together with the genomic
sequence that spans from exon 1 through exon 3 (Fig. 3A).
While P1PD drove CAT expression in both cell lines,
KBPE1-3 was only active in IGROV1 cells (Fig. 3B).
To de¢ne the region of the PstI^EcoRI KFR genomic frag-
ment regulating transcriptional and post-transcriptional
events, deletions at the 5P and 3P end of the KBPE1-3 con-
struct were generated and transiently transfected (Fig. 4).
CAT activity was analyzed together with the splicing pattern
of IGROV1 vs KB cell lines. The splicing pattern was assayed
by RT-PCR as described in Section 2. KBPE1-3, even though
less e⁄cient than P1PD (see Fig. 3B), exhibited an 18-fold
increase in speci¢city of expression in ovarian carcinoma cells
as compared to nasopharyngeal carcinoma cells. Detectable
levels of RT-PCR products were present in KB cells trans-
fected with KBPE1-3, although no CAT activity was observed
(see also Fig. 3B). Therefore, the lack of CAT translation
might rest in the presence of the six upstream ORF (uORFs)
in the part of downstream intron sequence of exon 3 con-
tained in the KBPE1-3 construct [4]. Deletion at the 5P end
of exon 1, corresponding at the ¢rst internal transcriptional
start site identi¢ed from an ovarian carcinoma cDNA expres-
sion library [7], was conducted to obtain the #4/6 ECO con-
struct. This construct compared to KBPE1-3 shown an in-
creased expression in both transfected cell lines (5-fold) with
no loss in speci¢city (CAT activity ratio: 18-fold in IGROV1
vs. KB cells). The #4/6 BAM construct, in which the 3P in-
tronic region containing the uORFs was deleted, was very
active in both cell lines and displayed a reduced speci¢city
ratio (2.5-fold in IGROV1 vs KB cells). Both the #4/6
BAM and #4/6 ECO constructs, as well as the KBPE1-3,
showed an imbalance between the amount of CAT transcripts
and activity suggesting also a regulation of transcript stability
and translation. Considering the activity of these constructs,
#4/6 ECO appeared to maintain the highest speci¢city,
Fig. 3. Reporter CAT gene activity in IGROV1 and KB transfected
cells. A: Chimeric KFR promoter-CAT constructs. B: A representa-
tive CAT reporter assay, with relevant positive (+) and negative (3)
controls, analyzed on a TLC plate.
Fig. 4. Analysis of 5P and 3P deleted P1^CAT constructs. IGROV1 and KB cells were transiently transfected with the chimeric CAT constructs
shown on the left. RT-PCR and CAT activity were analyzed as described in Section 2. CAT activities relative to that of the P1PD construct
are mean of duplicate determinations in three independent experiments; standard deviations were in the range * þ 0.01^0.3 and ** þ 0.6^0.9.
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although net gene expression was lower than in #4/6 BAM. A
further 3P deletion (#4/6 XBA construct), that removes the 5P
splice site of exon 3 together with the last 35 bp of the down-
stream intron, resulted in the vanishing of post-transcriptional
speci¢city and higher reporter activity. Interestingly, the lack
of the entire intron region of #4/6 XBA construct arose in an
equal amount of mature RNA in both cell lines.
4. Discussion
In the present study we have pointed out that the P1-driven
exon 3 containing mRNAs are more abundant in ovarian
KFR-expressing carcinoma cells than in the non-ovarian
KFR-expressing tumor cells (KB) and normal tissues. Thus,
we provided evidence that post-transcriptional events enhance
the speci¢city of the P1 promoter-driven gene expression in
ovarian carcinoma. Furthermore, we demonstrated that this
speci¢city is mainly related to the presence of the 5P splice site
and 35 bp intron region downstream of exon 3.
We have showed that only ovarian carcinoma cells are able
to e⁄ciently utilize the 3P and 5P consensus splice sites of exon
3 in the P1-derived pre-mRNA maturation process. Moreover
the results that we obtained with the construct that lacks the
5P splice site of exon 3 (#4/6 XBA), imply the presence of at
least one regulatory element in this region responsible for
ovarian exon 3 inclusion e⁄ciency. Indeed this construct dis-
plays the same reporter activity in both ovarian (IGROV1)
and non-ovarian (KB) cell lines (see Fig. 4). Note that the
intron III stretch of 35 bp, deleted from the construct #4/6
BAM to generate the construct #4/6 XBA, contains at least
two consensus elements: (i) the sequence GAGCAG homolo-
gous with SR binding site to SC35 [12],(ii) a G triplet se-
quence. The G triplet is an element frequently found in close
proximity to the 5P splice site and has been demonstrated to
be of predictive value for identi¢cation of exons in sequenced
genomic DNA [13,14]. A recent study provides the ¢rst ex-
perimental evidence that the K-globin G-rich elements interact
directly with the RNA component of the U1 snRNP, suggest-
ing that the recognition of such sequence by splicing factor(s)
may play an important role in 5P splice site selection in a large
number of pre-mRNAs [15].
In the same intron we also observed the presence of six
uORFs that shut o¡ the translation of the messenger in KB
but not in IGROV1 cells as demonstrated by the absence of
CAT activity but not of CAT mRNA in the KB cells trans-
fected with KBPE1-3 construct (see Fig. 3). Our data are in
keeping with the previous evidence that uORFs inhibit
mRNA translation [16] and that the inhibition can be exerted
in a cell speci¢c manner [17,18]. We also hypothesize in the 5P
terminus of KBPE1-3 construct the presence of a negative
regulator of transcription in KB cells.
Ovarian carcinoma is the major cause of death from gyne-
logical cancer. At diagnosis, the disease is often already dis-
seminated into the peritoneal cavity, and 28^35% of patients
survive overall no longer than 5 years [19]. New therapeutic
target speci¢c modalities on ovarian carcinomas are deeply
investigated: some are based on the targeting ability of mono-
clonal antibodies, others on the selective gene expression of
tumor-associated antigens [20,21]. A major limiting step of
gene therapy approach remains the delivery of toxic agents
speci¢cally to the tumor cells while sparing the surrounding
normal cells. At present, few tumor or tissue speci¢c pro-
moters have been identi¢ed [22] and some await an in vivo
demonstration of suitability. Our results point to the promise
of exploiting KFR P1 promoter region and additionally the
alternative splicing of exon 3 region in developing a speci¢c
gene therapy strategy against ovarian carcinoma. Indeed, be-
side the low level of P1-derived exon 3 containing KFR
mRNA detected in critical normal tissues such as lung and
kidney, the con¢nement of ovarian carcinoma within the peri-
toneal cavity suggest the sparing of these tissues during such
therapy.
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